
16.2K
Downloads
79
Episodes
The Off Script podcast offers in-depth interviews and discussions with industry experts about hot-button topics in pharma, and goes behind the scenes of Pharma Manufacturing’s print and online coverage, which follows the industry’s biggest issues surrounding scale-up, technology innovations, regulations and more
Episodes
![FDA approves biosim to Regeneron Eylea, Evotec exits gene therapy, J&J reports deaths in radioligand trial [The good, the bad, the ugly]](https://pbcdn1.podbean.com/imglogo/image-logo/9655061/Security_14__hjvhxj_300x300.jpg)
Tuesday May 28, 2024
Tuesday May 28, 2024
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:
The good — FDA approves first interchangeable biosims to Regeneron Eylea
The bad — Evotec exits gene therapy
The ugly — J&J reports deaths in early-stage radioligand trial
![FDA approves Amgen's T-cell engager for lung cancer, BioMarin announces layoffs, FDA delays Ascendis drug review [The good, the bad, the ugly]](https://pbcdn1.podbean.com/imglogo/image-logo/9655061/Security_14__hjvhxj_300x300.jpg)
Monday May 20, 2024
Monday May 20, 2024
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:
The good — FDA approves Amgen T-cell engager for small cell lung cancer
The bad — BioMarin announces 170 layoffs
The ugly — FDA delays review of Ascendis hypoparathyroidism drug
![Vertex submits NDA for CF drug, MacroGenics reports ADC prostate cancer trial patient deaths, FTC extends review of Novo-Catalent deal [The good, the bad, the ugly]](https://pbcdn1.podbean.com/imglogo/image-logo/9655061/Security_14__hjvhxj_300x300.jpg)
Monday May 13, 2024
Monday May 13, 2024
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:
The good — Vertex submits NDA for CF drug
The bad — MacroGenics reports patient deaths in prostate cancer ADC trial
The ugly — FTC extends review of Novo-Catalent deal
![Neurocrine wins FDA nod for 'sprinkle' Ingrezza, Moderna-Metagenomi deal ends, Emergent's layoffs [The good, the bad, the ugly]](https://pbcdn1.podbean.com/imglogo/image-logo/9655061/Security_14__hjvhxj_300x300.jpg)
Monday May 06, 2024
Monday May 06, 2024
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:
The good — Neurocrine wins FDA nod for 'sprinkle' Ingrezza formulation
The bad — Moderna, Metagenomi end gene editing collab
The ugly — Emergent announces layoffs, closes sites
![Novartis wins rare cancer pediatric indication, BMS layoffs, McKinsey under fire [The good, the bad, the ugly]](https://pbcdn1.podbean.com/imglogo/image-logo/9655061/Security_14__hjvhxj_300x300.jpg)
Monday Apr 29, 2024
Monday Apr 29, 2024
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:
The good — Novartis wins rare cancer pediatric indication for Lutathera
The bad — BMS unveils cost-saving initiative, layoffs
The ugly — McKinsey under fire for alleged role in opioid crisis
![GSK antibiotic hits phase 3 goals, Genentech-Adaptimmune collab ends, Par Pharma recall [The good, the bad, the ugly]](https://pbcdn1.podbean.com/imglogo/image-logo/9655061/Security_14__hjvhxj_300x300.jpg)
Monday Apr 22, 2024
Monday Apr 22, 2024
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:
The good — GSK antibiotic hits phase 3 goals in gonorrhea
The bad — Genentech ends $3B Adaptimmune T-cell collab
The ugly — Par Pharmaceutical recalls Treprostinil injection for potential contamination
![BMS schizophrenia drug shines, Novartis axes jobs, Lilly compounding suit dismissed [The good, the bad, the ugly]](https://pbcdn1.podbean.com/imglogo/image-logo/9655061/Security_14__hjvhxj_300x300.jpg)
Monday Apr 22, 2024
Monday Apr 22, 2024
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:
The good — BMS schizophrenia drug shines in phase 3 trial
The bad — Novartis to axe 680 jobs
The ugly — Lilly compounding suit dismissed

Friday Apr 12, 2024
2024 election's impact on manufacturing
Friday Apr 12, 2024
Friday Apr 12, 2024
Politics, whether we like them or not, weigh heavy on manufacturing’s future.
In case you haven’t heard, it is an election year! Which means, global trade, regulations, immigration, national security and taxation will all be part of the national discourse, and all of those topics touch on manufacturing in one way or another.
During this podcast, we will share a discussion courtesy of our sister brand, IndustryWeek, as part of their livestream program, Production Pulse. The broadcast features insights from Pharma Manufacturing’s chief content director Karen Langhauser as well as from editors on Machine Design and Food Processing.
![Basilea grabs FDA nod, Verve halts gene editing trial, Amylyx pulls ALS drug [The good, the bad, the ugly]](https://pbcdn1.podbean.com/imglogo/image-logo/9655061/Security_14__hjvhxj_300x300.jpg)
Monday Apr 08, 2024
Monday Apr 08, 2024
Editor's Review: Week of April 1
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:
The good — Basilea Pharmaceutica receives FDA approval for its IV antibiotic
The bad — Verve Therapeutics halts gene editing trial, again
The ugly — Amylyx removes ALS treatment from market
![[The good, the bad, the ugly] Editor's Review week of March 25](https://pbcdn1.podbean.com/imglogo/image-logo/9655061/Security_14__hjvhxj_300x300.jpg)
Monday Apr 01, 2024
[The good, the bad, the ugly] Editor's Review week of March 25
Monday Apr 01, 2024
Monday Apr 01, 2024
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:
The good — FDA approves Akebia Therapeutics' Vafseo anemia drug
The bad — Bristol Myers Squibb's Crohn's disease drug disappoints
The ugly — FDA rejects Regeneron Pharmaceuticals lymphoma treatment